{
    "clinical_study": {
        "@rank": "45374", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Ibuprofen", 
                "arm_group_type": "Active Comparator", 
                "description": "400 mg PO"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single center placebo controlled, prospective, randomized study on healthy adults\n      undergoing third molar surgery."
        }, 
        "brief_title": "Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Dental Pain", 
        "condition_browse": {
            "mesh_term": [
                "Pain, Postoperative", 
                "Toothache"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who provide written informed consent prior to enrollment\n\n          -  Male or female and 18 to 40 years of age\n\n          -  Patients who are scheduled to undergo elective ipsilateral two (2) third molar\n             extraction surgery under local anesthesia The mandibular  third molar must involve\n             full or partial bony impaction confirmed by radiographic evidence\n\n          -  Female subjects are eligible only if all of the following apply\n\n               -  Not pregnant (subjects of child bearing potential must have a negative urine\n                  beta human chorionic gonadotropin (\u03b2-hCG) pregnancy test before surgery)\n\n               -  Not lactating\n\n               -  Not planning to become pregnant within the duration of the study\n\n          -  Patients who are willing and capable of understanding and cooperating with the\n             requirements of the study\n\n          -  Patients able to understand and communicate in English\n\n        Exclusion Criteria:\n\n          -  Patients who have participated in a Lotus Clinical Research placebo response and pain\n             scale education training program\n\n          -  Patients with a medical condition that, in the Investigator's opinion, could\n             adversely impact the patient's participation, safety, or conduct of the study such as\n             but not limited to a history of severe renal or hepatic impairment, severe active\n             hepatic disease, other acute or chronic pain conditions, or any other clinically\n             significant medical condition\n\n          -  Patients who have a known history of intolerance, severe allergy or hypersensitivity\n             to Ibuprofen, opioid analgesics, Lidocaine, or acetaminophen (APAP)\n\n          -  Patients who have abused any prescription medication or alcohol within two years\n             before the start of the study\n\n          -  Patients who have surgical complications that could compromise safety of the subject\n             or confound the results of the study\n\n          -  The subject is taking any corticosteroid chronically (except for an inhaled steroid\n             for pulmonary disease) or has taken systemic corticosteroids within 4 weeks of the\n             proposed date of surgery\n\n          -  The subject is taking central nervous system (CNS) active drugs such as\n             benzodiazepines, tricyclic antidepressants, selective serotonin reuptake inhibitors\n             (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) for pain. These drugs\n             are permitted for non-pain indications throughout the study, if the dose has been\n             stable for at least 30 days\n\n          -  The subject has used acetylsalicylic acid, acetaminophen or nonsteroidal\n             antiinflammatory drug (NSAIDs) within 5 half-lives prior to  the planned day of the\n             surgery\n\n          -  The subject is taking an antihypertensive agent(s) or a diabetic regimen at a dose\n             that has not been stable for at least 28 days.\n\n          -  Patients who have a history of seizures, or are currently taking anticonvulsants\n\n          -  Patients who have dysphagia and/or cannot swallow study medication whole\n\n          -  Patient who is unable to adequately communicate with study staff, properly give\n             informed consent, or otherwise comply with study procedures\n\n          -  Patient who has participated in another clinical trial of an investigational drug or\n             device within 30 days of screening visit or is schedule to receive an investigational\n             product while participating in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096926", 
            "org_study_id": "LCR-DEN-01C"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ibuprofen", 
                "description": "400 mg PO", 
                "intervention_name": "Ibuprofen", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ibuprofen"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Third Molar Extraction", 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pasadena", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91105"
                }, 
                "name": "Lotus Clinical Research, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery", 
        "other_outcome": [
            {
                "measure": "Total Pain Relief (TOTPAR) 6", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Patient Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "6 hours post study drug administration"
            }
        ], 
        "overall_official": {
            "affiliation": "Lotus Clinical Research, LLC", 
            "last_name": "Sonia Singla, DO", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Sum of pain intensity difference (SPID)6", 
            "safety_issue": "No", 
            "time_frame": "6 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096926"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Sum of pain intensity difference (SPID) 3", 
            "safety_issue": "No", 
            "time_frame": "3 hour"
        }, 
        "source": "Lotus Clinical Research, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lotus Clinical Research, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}